周二,医疗器械制造商美国血液技术公司(HAE)公布了2024财年第三季度财报,超出市场预期,公司股价当日大涨7.47%,引发市场关注。
财报显示,美国血液技术第三季度调整后每股收益为1.12美元,高于分析师平均预期的1.07美元。该公司本季度营收同比增长8.6%,达到3.4551亿美元,虽略低于预期的3.4265亿美元,但整体表现依然出色。
分析师对美国血液技术的长期前景持乐观态度。目前分析师平均给予该公司"买入"评级,预计其未来12个月股价目标中位数为113.5美元。分析人士认为,作为医疗设备和用品行业的龙头企业,该公司在技术、研发和渠道优势等多方面具备良好发展潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.